A series of substituted benzylamines 2-48 were prepared as part of a strategy to identify structurally differentiated and synthetically more accessible selective serotonin reuptake inhibitors, relative to clinical candidate 1. In particular, 44 and 48; demonstrated low nanomolar potency and good selectivity, in a structurally simplified template and, in vivo, very low Vdu, significantly lower than l, and a more rapid T(max), consistent with our clinical objectives.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.bmcl.2008.06.001 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!